Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Investigating Group Iii Metabotropic Glutamate Receptors As Novel Therapeutic Targets In Parkinsons Disease And Levodopa Induced Dyskinesia
Download Investigating Group Iii Metabotropic Glutamate Receptors As Novel Therapeutic Targets In Parkinsons Disease And Levodopa Induced Dyskinesia full books in PDF, epub, and Kindle. Read online Investigating Group Iii Metabotropic Glutamate Receptors As Novel Therapeutic Targets In Parkinsons Disease And Levodopa Induced Dyskinesia ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Investigating Group III Metabotropic Glutamate Receptors as Novel Therapeutic Targets in Parkinson's Disease and Levodopa-induced Dyskinesia by :
Download or read book Investigating Group III Metabotropic Glutamate Receptors as Novel Therapeutic Targets in Parkinson's Disease and Levodopa-induced Dyskinesia written by and published by . This book was released on 2014 with total page 816 pages. Available in PDF, EPUB and Kindle. Book excerpt: Finally, since other antiglutamatergic strategies have proven successful, we investigated mGiu4 activation as a means to inhibit L-DOPA-induced dyskinesia expression or development in rodents. While this approach was ineffective at reversing established dyskinesia there was a hint that it might be efficacious at delaying the onset of this complication that will be worth investigating further. In conclusion, targeting the mGiu4 receptor has shown some beneficial effects in relation to Parkinson's disease but much remains to be discovered about the actions of these agents both within and outside of the basal ganglia before any clear potential is revealed.
Book Synopsis Therapeutic Potential of Targeting Group III Metabotropic Glutamate Receptors as a Disease Modifying Strategy in the Treatment of Parkinson's Disease by : Matthew Thomas John Betts
Download or read book Therapeutic Potential of Targeting Group III Metabotropic Glutamate Receptors as a Disease Modifying Strategy in the Treatment of Parkinson's Disease written by Matthew Thomas John Betts and published by . This book was released on 2011 with total page 690 pages. Available in PDF, EPUB and Kindle. Book excerpt: Parkinson's disease (PD) is characterised by a progressive loss of dopaminergic neurones from the SNpc, leading to numerous downstream changes in the basal ganglia circuitry. Overactivity of the glutamatergic subthalamonigral pathway may underlie this continual degeneration of the nigrostriatal system. With this in mind, this thesis examined whether selective activation of group III metabotropic glutamate receptor subtypes may offer a novel strategy to halt persistent degeneration in PD. -- Initial distribution studies revealed mGlu4 and 7 group III mGlu receptor subtypes, demonstrated particularly intense immunoreactivity in the SNpc, suggesting these receptors may be ideally positioned to provide neuroprotective effects. Therefore, the first objective was to confirm this neuroprotective possibility using a broad spectrum agonist, L-AP4. Sub-chronic supranigral L-AP4 treatment mediated functional neuroprotection against a unilateral 6-OHDA lesion of the SN, confirmed by behavioural assessment and post-mortem analyses. -- Secondly, the pharmacological identity of the group III mGlu receptor mediating this protective effect was examined. To investigate mGlu4 receptors, the novel mGlu4 selective PAM VU0155041, was also shown to provide functional neuroprotection in the 6-OHDA rat model to an almost comparable level reached with L-AP4. Whilst these neuroprotective effects are likely mediated by an inhibition of glutamate to protect from glutamate-mediated excitotoxicity, VUO15504 also led to a significant reduction in levels of GFAP and IBA-1 suggesting an additional anti-inflammatory action. Further studies revealed little evidence for co-localisation of mGlu4 receptors with GFAP in the SN suggesting this anti-inflammatory component likely reflects an indirect effect via stimulation of neuronal mGlu4 receptors.
Book Synopsis Group III Metabotropic Glutamate Receptors as Potential Targets in the Treatment of Parkinson's Disease by : Martin Broadstock
Download or read book Group III Metabotropic Glutamate Receptors as Potential Targets in the Treatment of Parkinson's Disease written by Martin Broadstock and published by . This book was released on 2006 with total page 538 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Metabotropic Glutamate Receptor MGluR4 as a Novel Target for Parkinson's Disease by :
Download or read book Metabotropic Glutamate Receptor MGluR4 as a Novel Target for Parkinson's Disease written by and published by . This book was released on 2001 with total page 213 pages. Available in PDF, EPUB and Kindle. Book excerpt: Parkinson's disease (PD) is characterized by a loss of substantia nigra dopaminergic neurons. Here we describe our progress in understanding the role of metabotropic glutamate receptors (mGluRs) as a novel target for the treatment of PD. We have localized mGluR4 in basal ganglia structures, and explored its role in mediating the electrophysiological effects of glutamate in rat brain slices. We have explored the efficacy of mGluR drugs in relieving motor symptoms in hemiparkinsonian monkeys. We found that group III mGluRs are presynaptic on striatal-pallidal terminals and that they mediate a reduction in IPSC amplitude in the SNr. They also pre-synaptically inhibit EPSCs at the STN-SNr synapse. In this study, we have found that groups I and II mGluRs also have critical roles in regulating basal ganglia function. Group II mGluRs mediate a presynaptic reduction of EPSCs in the SNr and group II agonist LY354740 reverses catalepsy in a rodent model of PD. Pre- and Post-synaptic group I mGluRs are involved in regulation of basal ganglia output nuclei by both excitation and disinhibition. Furthermore, comprehensive characterization of the roles of mGluRs in the basal ganglia raises the possibility that they may provide targets for novel therapeutic agents for treatment of PD.
Book Synopsis Metabotrobic Glutamate Receptor MGluR4 as a Novel Target for Parkinson's Disease by :
Download or read book Metabotrobic Glutamate Receptor MGluR4 as a Novel Target for Parkinson's Disease written by and published by . This book was released on 1999 with total page 170 pages. Available in PDF, EPUB and Kindle. Book excerpt: The symptoms of Parkinson's disease (PD) are associated with a loss of substantia nigra dopaminergic neurons involved in modulation of function of the basal ganglia (BG) . This report describes our progress in understanding the role of metabotropic glutamate receptors (mGluRs) as a novel target for the treatment of PD. Specifically, our aims are to localize mGluR4 in rat and monkey basal ganglia structures, to determine the role of this receptor vs. other subtypes in mediating the electrophysiological effects of glutamate in rat brain slices, and to determine the efficacy of drugs aimed mGluRs in relieving motor symptoms in hemi-parkinsonian monkeys. We found that group III mGluRs are presynaptic on striatal-pallidal terminals and that they mediate a reduction in IPSC amplitude in the SNr. Group III mGluRs also presynaptically inhibit EPSCs at the STN-SNr synapse. Group II mGluRs were found to mediate a presynaptic reduction of EPSCs in the SNr and group II agonist LY354740 reverses catalepsy in an animal model of PD. Furthermore, as these studies progress, the distribution and physiological roles of mGluRs in the BG raises the possibility that these receptors may provide targets for novel therapeutic agents for treatment of PD and related disorders.
Book Synopsis Assessing the Therapeutic Potential of Group III Metabotropic Glutamate Receptor Subtypes in Parkinson's Disease by : Paul Jonathon Austin
Download or read book Assessing the Therapeutic Potential of Group III Metabotropic Glutamate Receptor Subtypes in Parkinson's Disease written by Paul Jonathon Austin and published by . This book was released on 2008 with total page 678 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Statistics in the Paper Industry by :
Download or read book Statistics in the Paper Industry written by and published by . This book was released on 19?? with total page 81 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Study of Metabotropic Glutamate Receptor 5 in Parkinson's Disease and L-DOPA-induced Dyskinesia by : Naila I. Ismayilova
Download or read book Study of Metabotropic Glutamate Receptor 5 in Parkinson's Disease and L-DOPA-induced Dyskinesia written by Naila I. Ismayilova and published by . This book was released on 2003 with total page 235 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis A Synopsis of Parkinson's Disease by : Md, Frcpc, Frcp (hon), Abdul Qayyum Rana
Download or read book A Synopsis of Parkinson's Disease written by Md, Frcpc, Frcp (hon), Abdul Qayyum Rana and published by BoD – Books on Demand. This book was released on 2014-03-26 with total page 233 pages. Available in PDF, EPUB and Kindle. Book excerpt: Parkinsons disease is a disabling neurological condition with both motor and non-motor symptoms for which no cure is available at this stage. This book is unique in covering the most important topics related to Parkinsons disease. Current research and updates about some non-motor symptoms, as well as surgical treatment of Parkinsons disease, in addition to the long term complications of pharmacological treatments have been presented. This book can be used by physicians, researchers and neuroscientists who want to learn new information about these topics related to Parkinsons disease. Authors of the individual chapters are well known in their fields and the book has been edited by a world renowned Parkinsons disease expert.
Book Synopsis The Glutamate/GABA-Glutamine Cycle by : Arne Schousboe
Download or read book The Glutamate/GABA-Glutamine Cycle written by Arne Schousboe and published by Springer. This book was released on 2016-11-25 with total page 420 pages. Available in PDF, EPUB and Kindle. Book excerpt: Fundamental biochemical studies of basic brain metabolism focusing on the neuroactive amino acids glutamate and GABA combined with the seminal observation that one of the key enzymes, glutamine synthetase is localized in astroglial cells but not in neurons resulted in the formulation of the term “The Glutamate-Glutamine Cycle.” In this cycle glutamate released from neurons is taken up by surrounding astrocytes, amidated by the action of glutamine synthetase to glutamine which can be transferred back to the neurons. The conversion of glutamate to glutamine is like a stealth technology, hiding the glutamate molecule which would be highly toxic to neurons due to its excitotoxic action. This series of reactions require the concerted and precise interaction of a number of enzymes and plasma membrane transporters, and this volume provides in-depth descriptions of these processes. Obviously such a series of complicated reactions may well be prone to malfunction and therefore neurological diseases are likely to be associated with such malfunction of the enzymes and transporters involved in the cycle. These aspects are also discussed in several chapters of the book. A number of leading experts in neuroscience including intermediary metabolism, enzymology and transporter physiology have contributed to this book which provides comprehensive discussions of these different aspects of the functional importance of the glutamate-glutamine cycle coupling homeostasis of glutamatergic, excitatory neurotransmission to basic aspects of brain energy metabolism. This book will be of particular importance for students as well as professionals interested in these fundamental processes involved in brain function and dysfunction.
Book Synopsis Leucine-Rich Repeat Kinase 2 (LRRK2) by : Hardy J. Rideout
Download or read book Leucine-Rich Repeat Kinase 2 (LRRK2) written by Hardy J. Rideout and published by Springer. This book was released on 2017-03-28 with total page 280 pages. Available in PDF, EPUB and Kindle. Book excerpt: This is the first book to assemble the leading researchers in the field of LRRK2 biology and neurology and provide a snapshot of the current state of knowledge, encompassing all major aspects of its function and dysfunction. The contributors are experts in cell biology and physiology, neurobiology, and medicinal chemistry, bringing a multidisciplinary perspective on the gene and its role in disease. The book covers the identification of LRRK2 as a major contributor to the pathogenesis of Parkinson's Disease. It also discusses the current state of the field after a decade of research, putative normal physiological roles of LRRK2, and the various pathways that have been identified in the search for the mechanism(s) of its induction of neurodegeneration.
Book Synopsis Parkinson's Disease: Current and Future Therapeutics and Clinical Trials by : Néstor Gálvez-Jiménez
Download or read book Parkinson's Disease: Current and Future Therapeutics and Clinical Trials written by Néstor Gálvez-Jiménez and published by Cambridge University Press. This book was released on 2016-03-24 with total page 385 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book emphasizes treatment options for Parkinson's disease, providing the necessary clinical and scientific basis for the foundations of solid therapeutics.
Book Synopsis Homeostatic Control of Brain Function by : Detlev Boison
Download or read book Homeostatic Control of Brain Function written by Detlev Boison and published by Oxford University Press. This book was released on 2016 with total page 657 pages. Available in PDF, EPUB and Kindle. Book excerpt: Homeostatic Control of Brain Function offers a broad view of brain health and diverse perspectives for potential treatments, targeting key areas such as mitochondria, the immune system, epigenetic changes, and regulatory molecules such as ions, neuropeptides, and neuromodulators. Loss of homeostasis becomes expressed as a diverse array of neurological disorders. Each disorder has multiple comorbidities - with some crossing over several conditions - and often disease-specific treatments remain elusive. When current pharmacological therapies result in ineffective and inadequate outcomes, therapies to restore and maintain homeostatic functions can help improve brain health, no matter the diagnosis. Employing homeostatic therapies may lead to future cures or treatments that address multiple comorbidities. In an age where brain diseases such as Alzheimer's or Parkinson's are ever present, the incorporation of homeostatic techniques could successfully promote better overall brain health. Key Features include · A focus on the homeostatic controls that significantly depend on the way one lives, eats, and drinks. · Highlights from emerging research in non-pharmaceutical therapies including botanical medications, meditation, diet, and exercise. · Incorporation of homeostatic therapies into existing basic and clinical research paradigms. · Extensive scientific basic and clinical research ranging from molecules to disorders. · Emerging practical information for improving homeostasis. · Examples of homeostatic therapies in preventing and delaying dysfunction. Both editors, Detlev Boison and Susan Masino, bring their unique expertise in homeostatic research to the overall scope of this work. This book is accessible to all with an interest in brain health; scientist, clinician, student, and lay reader alike.
Book Synopsis Drug Induced Movement Disorders by : Stewart Factor
Download or read book Drug Induced Movement Disorders written by Stewart Factor and published by John Wiley & Sons. This book was released on 2008-04-15 with total page 480 pages. Available in PDF, EPUB and Kindle. Book excerpt: The second revised edition of this text will update and present current state of the art clinical approaches to this subject. This book will continue to be the source text of information on drug-induced movement disorders authored and edited by the pioneers in the field. It will be an invaluable addition to the library of any neurologist.
Book Synopsis The Metabotropic Glutamate Receptors by : P. Jeffrey Conn
Download or read book The Metabotropic Glutamate Receptors written by P. Jeffrey Conn and published by Springer Science & Business Media. This book was released on 2013-03-09 with total page 284 pages. Available in PDF, EPUB and Kindle. Book excerpt: The Metabotropic Glutamate Receptors offers state-of-the-art summaries and reviews of virtually everything known today about metabotropic glutamate receptors (mGluRs), including their molecular biology, pharmacology, anatomical distribution, and physiological and pathological roles. Illuminating the overall role played by this crucial class of receptors in brain function, the book also pinpoints those areas in which there is the greatest continuing need for focused research. Because mGluRs have the potential for participating in virtually all known functions of the central nervous system (CNS), the opportunity now exists to develop pharmacological agents that can potentially alter many brain disease processes by selective interaction with precise CNS functions. With its critical and insightful reviews, The Metabotropic Glutamate Receptors will immediately become your essential key to the development of novel treatment strategies for the widest variety of neurological disorders.
Book Synopsis The NMDA Receptor by : G. L. Collingridge
Download or read book The NMDA Receptor written by G. L. Collingridge and published by Oxford University Press, USA. This book was released on 1994 with total page 503 pages. Available in PDF, EPUB and Kindle. Book excerpt: Fingerprint Wizards is a Capstone Press publication.
Book Synopsis Progressive Brain Disorders in Childhood by : Juan M. Pascual
Download or read book Progressive Brain Disorders in Childhood written by Juan M. Pascual and published by Cambridge University Press. This book was released on 2017-04-20 with total page 507 pages. Available in PDF, EPUB and Kindle. Book excerpt: A review of childhood neurodegenerative and other progressive but non-degenerative disorders to guide their diagnosis and management.
